Canadian Myeloma Research Group
6 clinical trials · Sponsor
◉ Watch Canadian Myeloma Research Group
| Record | Firm | Date |
|---|---|---|
| Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients (NCT05272826) | Canadian Myeloma Research Group | 2024-12-12 |
| A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM (NCT04786028) | Canadian Myeloma Research Group | 2021-12-08 |
| A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE (NCT04258683) | Canadian Myeloma Research Group | 2021-02-17 |
| A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma (NCT03697629) | Canadian Myeloma Research Group | 2018-12-03 |
| Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex (NCT03715478) | Canadian Myeloma Research Group | 2018-11-26 |
| A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (NCT03215524) | Canadian Myeloma Research Group | 2017-10-25 |
Track Canadian Myeloma Research Group automatically
Every clearance here is in the API, with alerts when new ones post.